Effector Therapeutics Inc (EFTR) — Strategic Asset Allocation Index
Effector Therapeutics Inc (EFTR) has a Strategic Asset Allocation Index of 11.6% as of June 2023. Strategic assets (PP&E of $299.00K plus long-term investments of $-) total $299.00K, measured against net assets of $2.58 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See EFTR equity to assets ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Effector Therapeutics Inc Strategic Asset Allocation Index (2021–2022)
This chart shows how Effector Therapeutics Inc's Strategic Asset Allocation Index has evolved across 2 annual periods from 2021 to 2022. As of June 2023, the index stands at 11.6%, representing strategic assets of $299.00K against net assets of $2.58 Million USD. For live market cap and overall valuation, see Effector Therapeutics Inc (EFTR) market capitalisation.
Annual Strategic Asset Allocation Index for Effector Therapeutics Inc (2021–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Effector Therapeutics Inc from 2021 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Effector Therapeutics Inc book value and equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 9.0% | $352.00K | $352.00K | $- | $3.90 Million | ▲ +8.5 pp |
| 2021 | 0.5% | $91.00K | $91.00K | $- | $17.28 Million | — |